In what comes as an important update regarding the vaccine candidate being developed by the University of Oxford, AstraZeneca pharmaceuticals, and IQVIA – the AZD1222, formerly called the (ChAdOx1 nCoV-19), the lead developer has now said that there is a chance that the vaccine could roll out by the end of the year, although there is no certainty that it will happen.
The vaccine candidate developed at the University of Oxford has shown encouraging results in early human testing and appears to be “safe well-tolerated, and immunogenic”, the findings of the trial published in The Lancet journal said yesterday.
“The end of the year target for getting vaccine rollout, it’s a possibility but there’s absolutely no certainty about that because we need three things to happen,” lead developer for the vaccine, Sarah Gilbert, told BBC Radio.
According to the researchers working on the vaccine, there need to be three conditions fulfilled in order for the vaccine, now still a prototype, to roll out for the public by this year-end. These factors are successful late-stage trials, manufacturing in large quantities, and rapid licensing by regulators for emergency use.
Only if these three conditions are met can the AZD1222 coronavirus vaccine be expected to be out by the year-end, but since these are widely variable factors, there is no certainty that it will, Gilbert said in the interview.
This vaccine prototype is considered to be the most advanced one among all the samples currently in development. It is currently in large-scale Phase-III trials, which typically involve more participants, including a control group, and test effectiveness of the vaccine to prevent the disease (an “interventional” trial), while monitoring for adverse effects at the optimal dose.
This prototype was developed at the University of Oxford and the Jenner Institute. Earlier, the scientists developing the vaccine at Oxford University had aimed for a September roll-out date.
A UK Phase I/II trial began in April testing the Oxford coronavirus vaccine ChAdOx1 nCoV-19. The team started working to develop a vaccine against the global threat that is coronavirus in January 2020 and have been working with unprecedented urgency in a race against the coronavirus.
The next step in studying the vaccine is to confirm that it can effectively protect against SARS-CoV-2 infection.
The University of Oxford is working with the UK-based global biopharmaceutical company AstraZeneca for further development, large-scale manufacture, and potential distribution of the Covid-19 vaccine, with plans for clinical development and production of the Oxford vaccine progressing globally. The project has been further spurred by £84 million of Government funding to help accelerate the vaccine’s development.